Telomir Pharmaceuticals is positioning itself at the forefront of longevity science with its lead candidate Telomir-1, a small molecule designed to address fundamental aging mechanisms. The company plans to leverage the BIO International Convention 2025 to explore potential partnerships and advance its preclinical-stage therapeutic development.
The drug candidate shows promising potential across multiple disease areas, including rare genetic conditions like Progeria and Werner's syndrome, as well as more common age-related diseases such as Type 2 diabetes, aggressive prostate cancer, and macular degeneration. By targeting telomere elongation, Telomir-1 represents a novel approach to addressing cellular aging and potential disease progression.
Telomir aims to submit an Investigational New Drug application to the FDA by the end of this year, with plans to initiate first-in-human dosing in the first half of 2026. The company is actively seeking FDA guidance on developing innovative clinical endpoints to potentially accelerate the drug's development pathway.
The pharmaceutical's approach focuses on addressing telomere shortening, a key biological mechanism associated with aging. As telomeres naturally degrade over time, they increase susceptibility to degenerative diseases. Telomir-1's potential oral dosing could represent a significant breakthrough in longevity and disease prevention research.
By participating in the BIO International Convention's partnering program, Telomir is strategically positioning itself to explore licensing, mergers and acquisitions, and potential strategic collaborations that could expedite the development and potential commercialization of its groundbreaking therapeutic approach.
